REDWOOD CITY, Calif.,
Aug. 8, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a
specialty pharmaceutical company focused on innovative therapies
for use in medically supervised settings, today announced that the
underwriters of its previously announced underwritten public
offering have exercised in full their option to purchase an
additional 1,090,909 shares of AcelRx's common stock. Including
this option exercise, total gross proceeds to AcelRx from the
offering of an aggregate 8,363,636 shares at a price to the public
of $2.75 per share were approximately
$23.0 million, before deducting the
underwriting discounts and commissions and other offering expenses
payable by AcelRx. The sale of option shares was closed on
August 7, 2018.
Cantor Fitzgerald & Co. acted as the sole book-running
manager for the offering. H.C. Wainwright & Co. acted as lead
manager for the offering. Ladenburg Thalmann acted as co-manager
for the offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
filed with the Securities and Exchange Commission (the "SEC") and
is effective. The offering was made solely by means of a
prospectus supplement and accompanying prospectus which were filed
with the SEC and are available on the SEC's web site at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus may also be obtained by contacting Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
6th Floor, New York, NY 10022 or
by e-mail at prospectus@cantor.com.
This press release does not constitute an offer to sell, a
solicitation of an offer to sell or a solicitation of an offer to
buy the securities described herein, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates including DSUVIA™ (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO™ outside the United States, with a proposed indication
for the treatment of moderate-to-severe acute pain in medically
supervised settings, and Zalviso® (sufentanil sublingual tablet
system, SST system, 15 mcg) being developed as an innovatively
designed patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-300693599.html
SOURCE AcelRx Pharmaceuticals, Inc.